Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

Rhea-AI Summary

Guardant Health, a leading precision oncology company (Nasdaq: GH), partners with Hikma Pharmaceuticals PLC to promote its cancer screening and tumor mutation profiling tests in the Middle East and North Africa. The agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in the majority of countries in the MENA region. This partnership aims to improve access to next-generation sequencing tests in a region where cancer cases are estimated to double by 2040.

Market Research Analyst

The agreement between Guardant Health and Hikma Pharmaceuticals to commercialize a range of cancer diagnostic tests in the MENA region represents a strategic expansion for Guardant Health. This move is likely to increase the company's market share and revenue potential in an area where cancer cases are projected to rise significantly. From a market perspective, the exclusivity of the rights granted to Hikma could provide a competitive edge in the regional market, potentially increasing the demand for Guardant Health's tests.

Furthermore, the partnership leverages Hikma's established distribution network and regional expertise, which could enhance market penetration and adoption rates. The introduction of next-generation sequencing (NGS) tests can be a game-changer for the region, offering a more personalized approach to cancer care. This could lead to a shift in treatment paradigms and potentially increase the overall addressable market for precision oncology solutions.

Medical Research Analyst

The collaboration between Guardant Health and Hikma Pharmaceuticals underscores the importance of precision medicine in oncology. Next-generation sequencing (NGS) tests, such as those offered by Guardant Health, are at the forefront of individualized cancer treatment. These tests can detect minimal residual disease and guide therapy, which is crucial for improving patient outcomes.

By enabling early detection and precise tumor profiling, these tests can facilitate timely and appropriate treatment interventions. The availability of such advanced diagnostics in the MENA region could lead to a significant improvement in cancer management, potentially reducing mortality rates and improving the quality of life for patients. As cancer cases are expected to double by 2040 in the region, the impact of this partnership could be substantial in terms of public health outcomes.

Financial Analyst

The announcement of Guardant Health's partnership with Hikma Pharmaceuticals is likely to be viewed positively by investors, as it signals both growth and expansion into new markets. The partnership could lead to an increase in Guardant Health's earnings projections, given the potential market size and the increasing incidence of cancer in the MENA region.

Investors should monitor the uptake of Guardant Health's tests in the new markets and the impact on the company's financials. The ability of Hikma to effectively commercialize these products will be critical for the success of this venture. It is important to consider the costs associated with market entry and the time it may take to realize returns on investment. However, if successful, the partnership could contribute significantly to Guardant Health's long-term revenue growth and strengthen its global market position.

PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling for all solid cancers across the Middle East and North Africa (MENA).

The partnership expands Guardant Health's global presence and includes products across the cancer care continuum. The tests offered include Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360^® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers. This agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in a majority of countries in the MENA region.

Guardant Health serves more than 60 countries globally with its tests, and this partnership with Hikma will improve access to Guardant's next-generation sequencing (NGS) tests in the Middle East and North Africa, where cancer cases are estimated to double by the year 2040.^[1]

"Guardant Health is excited to partner with Hikma and leverage their strong commercial capabilities and regional expertise to equip oncologists in MENA with the necessary tools for cancer screening, recurrence monitoring and guiding treatment selection," said Simranjit Singh, Guardant Health AMEA CEO. "We are committed to improving patient outcomes globally by offering next-generation sequencing tests across all stages of the disease. Today, an increasing number of patients with cancer are being detected at the advanced stage, making it more crucial to match these patients to appropriate therapies in a timely manner. Ultimately, our goal is to make cancer screening easy and effective so that we can detect cancer earlier when it's most treatable."

"Our partnership with Guardant Health adds next-generation sequencing diagnostics that can potentially transform cancer care in MENA bringing hope to patients facing this challenging journey. We are excited to partner with Guardant Health, as their offering can help patients at all stages of the disease – from screening to monitoring cancer recurrence to guiding treatment decisions. As a leading healthcare company in MENA with a robust oncology portfolio encompassing generics, biologics, immunotherapy, and cutting-edge innovations, Hikma is committed to advancing precision medicine for improved treatment outcomes in patients with cancer," said Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA. 

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

About Hikma

 (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Reference

1. Mahdi H, Mula-Hussain L, Ramzi ZS, et al. Cancer Burden Among Arab-World Females in 2020: Working Toward Improving Outcomes. JCO Glob Oncol. 2022;8:e2100415. doi:10.1200/GO.21.00415

View original content to download multimedia:https://www.prnewswire.com/news-releases/guardant-health-and-hikma-partner-to-offer-cancer-screening-and-comprehensive-genomic-profiling-tests-in-the-middle-east-and-north-africa-302028144.html

SOURCE Guardant Health

What is the ticker symbol for Guardant Health?

The ticker symbol for Guardant Health is GH.

What products are included in the partnership between Guardant Health and Hikma Pharmaceuticals?

The partnership includes Guardant Health's Shield™ for cancer screening, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring, and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.

What is the goal of the partnership between Guardant Health and Hikma Pharmaceuticals?

The goal is to improve access to next-generation sequencing tests in the Middle East and North Africa, where cancer cases are estimated to double by 2040, and to equip oncologists with the necessary tools for cancer screening, recurrence monitoring, and guiding treatment selection.

How many countries does Guardant Health serve with its tests?

Guardant Health serves more than 60 countries globally with its tests.

Who is the CEO of Guardant Health AMEA?

The CEO of Guardant Health AMEA is Simranjit Singh.